

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number
WO 03/086361 A1

- (51) International Patent Classification⁷: **A61K 9/20**, 31/4178, 31/5513
- (21) International Application Number: **PCT/IB02/01272**
- (22) International Filing Date: **18 April 2002 (18.04.2002)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (71) Applicant (for all designated States except US): **DR. REDDY'S LABORATORIES LTD.** [IN/IN]; P.O. Box No. 15, Kukatpally, 500 072 Hyderabad (Andhra Pradesh) (IN).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **DIVI, Muralikrishna** [IN/IN]; Dr. Reddy's Laboratories Ltd., P.O. Box No. 15, Kukatpally, 500 072 Hyderabad (Andhra Pradesh) (IN). **DESHMUKH, Abhijit, Mukund** [IN/IN]; Dr. Reddy's Laboratories Ltd., P.O. Box No. 15, Kukatpally, 500 072 Hyderabad (Andhra Pradesh) (IN). **DHANORKAR, Vipin, Tatyasaheb** [IN/IN]; Dr. Reddy's Laboratories Ltd., P.O. Box No. 15, Kukatpally, 500 072 Hyderabad (Andhra Pradesh) (IN). **MOHAN, Mailatur, Sivaraman** [IN/IN]; Dr. Reddy's Laboratories Ltd., P.O. Box No. 15, Kukatpally, 500 072 Hyderabad (Andhra Pradesh) (IN).
- (74) Common Representative: **DR. REDDY'S LABORATORIES LTD.**; P.O. Box No. 15, Kukatpally, 500 072 Hyderabad (Andhra Pradesh) (IN).
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.**
- (84) Designated States (regional): **ARIPO** patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), **Eurasian** patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), **European** patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), **OAPI** patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **RAPIDLY DISPERSING SOLID ORAL COMPOSITIONS**

(57) Abstract: The present invention relates to the rapidly dispersing solid oral compositions comprising Olanzapine or Ondansetron. The present invention further discloses the wet granulation or direct compression method of producing such rapidly dispersing compositions. The pharmaceutically accepted solvate, salts, enantiomers or mixtures thereof including racemic mixture of Olanzapine and Ondansetron are contemplated to be within the scope of the present invention.

WO 03/086361 A1

5 RAPIDLY DISPERSING SOLID ORAL COMPOSITIONS

FIELD OF THE INVENTION

The present invention relates to the rapidly dispersing solid oral composition and process for manufacture of such compositions.

10

DESCRIPTION OF THE RELEVANT ART

Oral administration in the form of a conventional tablet, pill or capsule constitutes the generally preferred route for administration of pharmaceuticals since this route is generally convenient and acceptable to patients. Unfortunately such compositions may be associated with certain
15 disadvantages, particularly in the treatment of pediatric or geriatric patients, who may dislike or have difficulty in swallowing such compositions, or where administration of a conventional tablet, pill or capsule is not feasible.

In case of patients with psychosis and other mental disorders the administration of conventional
20 solid dosage form is not always suitable due to patient compliance. In case of disorders where water intake needs to be limited or patients have reduced tendency to drink water for eg. Nausea, the use of rapidly dispersing tablet is suitable choice as it can be swallowed without water and disintegrates rapidly when it enters stomach.

25 U.S. Pat. No. 5,955,488 and 6,063,802 discloses that the Ondansetron hydrochloride dihydrate has bitter taste. In order to solve this problem the patents teaches the use of Ondansetron base in the form of freeze dried dosage form for oral administration. However, such freeze dried dosage form suffers from various drawbacks such as moisture sensitivity, inherent fragility and such like. This causes most of the operations like embossing, packing and handling of such product a
30 difficult and cumbersome operation. In particular, it has been determined that, due to the inherent fragility, surface undulation, moisture sensitivity and chemical makeup of freeze-dried dosage forms, the application of compression for the purpose of embossing would cause deformation, reduced porosity and hence increased dispersion time, and possibly cracking of the dosage forms. Similarly, it is believed that the chemical makeup, moisture sensitivity, porosity
35 and surface undulation of freeze dried dosage forms would cause ink to dissolve the dosage forms at the point of contact or to diffuse throughout the dosage forms leading to clarity problems. The said freeze dried products are also generally not suited for packing and handling

5 temperature in the range of -30 to 25°C to other tablet components, cooling the mixture below the freezing temperature to solidify the liquid; tableting the cooled mixture; and then evaporating the liquid. However, this process suffers from low productivity.

10 Accordingly, it is an object of the present invention to provide a rapidly dispersing solid oral composition comprising Ondansetron, Olanzapine along with pharmaceutically accepted salts, solvates, enantiomers or mixtures thereof including racemic mixture and method of producing such compositions.

SUMMARY OF THE INVENTION

15 The invention relates to the rapidly dispersing compositions and method of producing such compositions. The present invention uses substantially simple and cost effective manufacturing technique. The rapidly dispersible tablets prepared by such process has acceptable stability as per ICH guidelines and dispersed within 30 seconds preferably within 10 seconds and more preferably within 5 seconds. The rapidly dispersible compositions obtainable according to the
20 invention, in addition to being dispersed rapidly have the following further advantages:

- It has substantially good organoleptic characteristics;
- It is devoid of any need for the cautions and measures required during handling and packaging of the freeze dried formulations;
- It avoids the use of organic solvents which might pose environmental safety problems

25 According to one of the embodiments of the invention the active ingredient along with one or more pharmaceutical excipients was blended for 5-10 minutes, the powder blend thus obtained was granulated with solution of wetting agent/surfactant in water, the wet mass thus obtained was sieved to obtain granules. The granules after drying were compressed into the tablets. Alternatively the tablets can be prepared using direct compression technique.

30

DETAILED DESCRIPTION OF THE INVENTION

The present invention therefore provides the rapidly dispersing tablet formulation for oral administration comprising an active ingredient, in the form of its free base or pharmaceutically accepted salts, solvate, enantiomers or mixtures thereof including racemic mixture and one or
35 more pharmaceutically accepted excipients.

As used in this description and in the appended claims the word "rapidly dispersing" refers to the dosage form which disperses in water within 30 seconds, preferably within 10 seconds and more

5 preferably within 5 seconds or less as per the test specified in United States Pharmacopoeia.

In the description and in the appended claims the word "pharmaceutically active ingredient" refers to any of the drug selected from ondansetron, olanzapine or pharmaceutically accepted salts, solvate, enantiomers or mixtures thereof including racemic mixture.

10

The term "pharmaceutically accepted excipients" as used in this description and in the appended claims comprise binders, dispersing agents, fillers, flavoring agents, sweetening agents, lubricants or glidants and such like. The "dispersing agent" in accordance with the present invention comprises crosscarmellose sodium, crosscarmellose calcium, crosspovidone, sodium
15 starch glycolate, sodium carboxymethyl cellulose, hydroxypropylcellulose, xanthan gum, alginic acid and alginates one or more clays selected from bentonite, hectorite, magnesium aluminium silicate, and such like, preferably the dispersing agent used in the present invention is crosspovidone.

20 The "binders" used in the present invention are selected from gelatin, pregelatinized starch, starch paste, starch DC, starch 1500, acacia, tragacanth, guar gum, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, glucose, sucrose, sorbitol, polyvinylpyrrolidone plasdone S-630 and such like. The preferred binder of the present invention is pregelatinized starch.

25

Suitable "fillers" as used in this invention are selected from one or more starch derivatives selected from corn starch, potato starch or rice starch; one or more polysaccharides selected from the group consisting of dextrans or maltodextrins, microcrystalline cellulose, powdered cellulose, mixture of microcrystalline cellulose and guar gum, coprocessed blends of microcrystalline
30 cellulose; one or more polyhydric alcohols selected from the group consisting of mannitol, xylitol, sorbitol and such like. The preferred fillers used in this invention are mannitol, microcrystalline cellulose and mixture of microcrystalline cellulose and guar gum.

35

The "surfactant or wetting agent" as used in this specification and in the appended claims is selected from any of polyoxyethylene sorbitan fatty acid esters, e.g., polyoxyethylene 20 sorbitan monolaurate (TWEEN 20), polyoxyethylene (4) sorbitan monolaurate (TWEEN 21), polyoxyethylene 20 sorbitan monopalmitate (TWEEN 40), polyoxyethylene 20 sorbitan monooleate (TWEEN 80); polyoxyethylene alkyl ethers, e.g., polyoxyethylene 4 lauryl

5 ether (BRIJ 30), polyoxyethylene 23 lauryl ether (BRIJ 35), polyoxyethylene 10 oleyl ether (BRIJ 97); and polyoxyethylene glycol esters, e.g., polyoxyethylene 8 stearate (MYRJ 45), polyoxyethylene 40 stearate (MYRJ 52) or mixtures thereof, or sodium lauryl sulphate and such like. The preferred surfactant of the present invention is sodium lauryl sulphate.

10 The suitable "lubricants" are talc, magnesium stearate, stearic acid or glyceryl behenate preferably magnesium stearate and suitable glidants includes colloidal silicon dioxide or talc preferably colloidal silicon dioxide.

Suitable "sweeteners" include, for example, sugars such as sucrose, lactose and glucose;
15 cyclamate and salts thereof; saccharin and salts thereof; and aspartame. Preferably the sweetener of the rapidly dispersing dosage form of the present invention is aspartame. Suitable flavoring agent include strawberry, cherry, mint and caramel flavouring aids, preferably the flavoring agent of the present invention is strawberry flavour.

20 Within the above preferred aspects of the invention, rapidly dispersing composition, wherein the amount of active ingredient is in the range of 1 to 25 mg. When the pharmaceutically active ingredient is Ondansetron or a free base, salt, solvate, enantiomer or mixture thereof including racemic mixture, the preferred amount is 4, 8, 16 or 24 mg. When the pharmaceutically active ingredient is Olanzapine or a free base, salt, solvate, enantiomer or mixture thereof including
25 racemic mixture, the preferred amount is 5, 10, 15 or 20 mg.

It is worth to mention that though examples given in the present description are limited to the particular amount of dosage form, it is obvious to those skilled in the art to find out the composition for other dosage forms and substitute the equivalent excipients as described in this
30 specification or with the one known to the industry.

The following examples describe the present invention in detail but does not limit the invention in any way.

5 **Example 1.**

Ondansetron 4 mg rapidly dispersing tablet:

SN	Ingredients	Quantity in mg
1.	Ondansetron	4
2.	Microcrystalline cellulose (Avicel 101)	16.5
3.	Mannitol	2.5
4.	Pregelatinized starch	2.5
5.	Crosspovidone	5
6.	Aspartame	2
7	Colloidal silicon dioxide	1
8	Magnesium stearate	0.5
9	Microcrystalline cellulose (Avicel 112)	12.85
10	Microcrystalline cellulose and Guar gum (Avicel CE 15)	2.5
11	Sodium lauryl sulphate	0.15
12	Strawberry Flavor	0.5

Preparation method:

- 10 1. Ingredients 1 to 4 and half quantity of ingredient 5 were weighed and passed through mesh #60 and blended for 5–10 minutes.
2. The powder blend obtained from step (1) was granulated with the solution of sodium lauryl sulphate (ingredient 11) in water to obtain wet mass.
3. The wet mass of step (2) was passed through mesh # 10 to obtain wet granules. The wet granules were dried at suitable temperature from 40⁰C-65⁰C till the LOD (Loss on
15 drying) of the granules was 2% or less.
4. The dried granules of step (3) were passed through mesh # 30.
5. Ingredients 6 to 10, 12 and remaining half the quantity of ingredients 5 were weighed and passed through mesh # 40 and blended with dried granules obtained from step (4) to obtain lubricated blend.
- 20 6. The lubricated blend of step (5) was compressed to tablets using suitable punches.

5 Example 2.

Ondansetron 8mg rapidly dispersing tablet:

SN	Ingredients	Quantity in mg
1	Ondansetron	8
2	Microcrystalline cellulose (Avicel 101)	33
3	Mannitol	5
4	Pregelatinized starch	5
5	Crosspovidone	10
6	Aspartame	4
7	Colloidal silicon dioxide (Aerosil 200)	2
8	Magnesium stearate	1
9	Microcrystalline cellulose (Avicel 112)	25.7
10	Microcrystalline cellulose and Guar gum (Avicel CE 15)	5
11	Sodium lauryl sulphate	0.3
12	Strawberry Flavor	1

Procedure: Same as in example 1.**Example 3:**

Ondansetron 24 mg rapidly dispersing tablet:

SN	Ingredients	Quantity in mg
1	Ondansetron	24
2	Microcrystalline cellulose (Avicel 101)	60
3	Sorbitol	15
4	Plasdone S-630	10
5	Crosscarmellose sodium	27
6	Aspartame	10
7	Colloidal silicon dioxide (Aerosil 200)	6
8	Lubritalc	3
9	Microcrystalline cellulose (Avicel 112)	40.4
10	Microcrystalline cellulose and Guar gum (Avicel CE 15)	15
11	Tween 80	0.6
12	Strawberry Flavor	3

5 **Procedure:** Same as in Example 1.

Example 4:

Ondansetron 4 mg rapidly dispersing tablet:

SN	Ingredients	Quantity in mg
1	Ondansetron	4
2	Crosspovidone	33.86
3	Aspartame	1.5
4	Magnesium stearate	1
5	Microcrystalline cellulose and Guar gum (Avicel CE 15)	4
6	Sodium lauryl sulphate	0.135
7	Strawberry Flavor	0.5

Preparation method:

1. Ingredients 1 to 3 were weighed and passed through mesh #80 and blended for 5 – 10 minutes.
2. The blend obtained from step (1) was granulated with solution of sodium lauryl sulphate (ingredient 6) in water in FBP (fluid bed processor) and dried.
3. After completion of drying process, ingredients 4, 5, and 7 were charged in to the fluid bed processor and mixed for 3 minutes at 30°C, to obtain a lubricated blend.
4. The lubricated blend of step (3) was passed through mesh # 40 and compressed into tablets using suitable punches.

Example 5.

Ondansetron 8mg rapidly dispersing tablet:

SN	Ingredients	Quantity in mg
1	Ondansetron	8
2	Crosspovidone	67.73
3	Aspartame	3
4	Magnesium stearate	2
5	Microcrystalline cellulose and Guar gum (Avicel CE 15)	8
6	Sodium lauryl sulphate	0.27
7	Strawberry Flavor	1

- 5 Preparation method: Same as in example 4.

Example 6.

Ondansetron 24 mg rapidly dispersing tablet:

SN	Ingredients	Quantity in mg
1	Ondansetron	24
2	Crosspovidone	70
3	Aspartame	9
4	Lubritalc	6
5	Microcrystalline cellulose and Guar gum (Avicel CE 15)	24
6	Tween 80	0.81
7	Strawberry Flavor	3

Same as in example 4.

Example 7.

- 10 Olanzapine 5 mg rapidly dispersing tablet:

SN	Ingredients	Quantity in mg
1	Olanzapine	5
2	Microcrystalline cellulose (Avicel 101)	15.5
3	Mannitol	2.5
4	Pregelatinized starch	2.5
5	Crosspovidone	5
6	Aspartame	2
7	Colloidal silicon dioxide (Aerosil 200)	1
8	Magnesium stearate	0.5
9	Microcrystalline cellulose (Avicel 112)	12.85
10	Microcrystalline cellulose and Guar gum (Avicel CE 15)	2.5
11	Sodium lauryl sulphate	0.15
12	Strawberry Flavor	0.5

5 **Preparation method**

The similar method as described in example 1 was adopted for the preparation of above mentioned tablets.

Example 8.

Olanzapine 10 mg rapidly dispersing tablet:

SN	Ingredients	Quantity in mg
1	Olanzapine	10
2	Microcrystalline cellulose (Avicel 101)	10.5
3	Mannitol	2.5
4	Pregelatinized starch	2.5
5	Crosspovidone	5
6	Aspartame	2
7	Colloidal silicon dioxide (Aerosil 200)	1
8	Magnesium stearate	0.5
9	Microcrystalline cellulose (Avicel 112)	12.85
10	Microcrystalline cellulose and Guar gum (Avicel CE 15)	2.5
11	Sodium lauryl sulphate	0.15
12	Strawberry Flavor	0.5

10

Preparation method:

The similar method as described in example 1 was adopted for the preparation of above mentioned tablets.

5 **Example 9.**

Olanzapine 20 mg rapidly dispersing tablet:

SN	Ingredients	Quantity in mg
1	Olanzapine	20
2	Microcrystalline cellulose (Avicel 101)	21
3	Sorbitol	5
4	Hydroxypropylmethylcellulose	5
5	Alginic acid and Sodium starch glycolate	12
6	Aspartame	4
7	Colloidal silicon dioxide (Aerosil 200)	2
8	Glyceryl behenate	1
9	Microcrystalline cellulose (Avicel 112)	25.7
10	Microcrystalline cellulose and Guar gum (Avicel CE 15)	5
11	Tween 80	0.3
12	Strawberry Flavor	1

Preparation method:

The similar method as described in example 1 was adopted for the preparation of above mentioned tablets.

10 **Example 10.**

Olanzapine 5 mg rapidly dispersing tablet:

SN	Ingredients	Quantity in mg
1	Olanzapine	5
2	Crosspovidone	32.86
3	Aspartame	1.5
4	Magnesium stearate	1
5	Microcrystalline cellulose and Guar gum (Avicel CE 15)	4
6	Sodium lauryl sulphate	0.135
7	Strawberry Flavor	0.5

Preparation method:

The similar method as described in example 4 was adopted for the preparation of above mentioned tablets.

5 **Example 11.**

Olanzapine 10 mg rapidly dispersing tablet:

SN	Ingredients	Quantity in mg
1	Olanzapine	10
2	Crosspovidone	27.86
3	Aspartame	1.5
4	Magnesium stearate	1
5	Microcrystalline cellulose and Guar gum (Avicel CE 15)	4
6	Sodium Lauryl Sulfate	0.135
7	Strawberry Flavor	0.5

Preparation method:

10 The similar method as described in example 4 was adopted for the preparation of above mentioned tablets.

Example 12.

Olanzapine 20 mg rapidly dispersing tablet:

SN	Ingredients	Quantity in mg
1	Olanzapine	20
2	Crosspovidone	55.73
3	Aspartame	3
4	Magnesium stearate	2
5	Microcrystalline cellulose and Guar gum (Avicel CE 15)	8
6	Sodium lauryl sulphate	0.27
7	Strawberry Flavor	1

Preparation method:

15 The similar method as described in example 4 was adopted for the preparation of above mentioned tablets.

It is obvious to those skilled in the art that both the methods of wet granulation and direct compression can be suitably and successfully applied for the preparation of the tablets as per any

- 5 of the examples 1 to 10. When direct compression method is used in the manufacture of tablets the water and sodium lauryl sulphate is not needed in the formulation which is exemplified by the following example.

Example 13.

Olanzapine/Ondansetron rapidly dispersing tablets:

SN	Ingredients	% W/W
1	Olanzapine/ Ondansetron	22.22
2	Crosspovidone	62.22
3	Aspartame	3.33
4	Magnesium stearate	2.22
5	Microcrystalline cellulose and Guar gum (Avicel CE 15)	8.88
6	Strawberry Flavor	1.11

10

Preparation procedure:

All the ingredients 1-6 are passed through mesh # 40 and blended in suitable blender for 5-10 minutes and compressed into tablets using suitable punches.

- 15 The examples given above are only meant to be explanatory and in no way limit the scope of the present invention. Many variation of the present invention, disclosed in the detailed description, are obvious to those skilled in the art and are contemplated to be within the scope of the present invention.

WE CLAIM:

1. Rapidly dispersing solid oral composition comprising Ondansetron or a pharmaceutically accepted salts, solvates, enantiomers or mixtures thereof including racemic mixture, in an amount of 1 mg to 25 mg, with at least one pharmaceutically accepted excipients selected from the group consisting of an at least one binder in an amount of 2% to 10%, an at least one dispersing agent in an amount of 5% to 15%, an at least one filler in an amount of 50% to 75%, an at least one glidants or lubricant in an amount of 0.5% to 5% and an at least one sweetener in an amount of 1% to 6%.
2. The composition of claim 1 comprising the binders selected from the group consisting of gelatin, pregelatinized starch, starch paste, starch DC, starch 1500, acacia, tragacanth, guar gum, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, glucose, sucrose, sorbitol, polyvinylpyrrolidone or plasdone S-630.
3. The composition of claim 1 comprising the dispersing agent selected from the group consisting of crosscarmellose sodium, sodium carboxymethyl cellulose, crosspovidone, sodium starch glycolate, hydroxypropylcellulose, hydroxypropylmethylcellulose, xanthan gum, alginic acid, alginates or bentonite.
4. The composition of claim 1 comprising the fillers selected from the group consisting of one or more starch derivatives selected from corn starch, potato starch or corn starch one or more polysaccharides selected from the group consisting of dextrans, maltodextrin, microcrystalline cellulose, powdered cellulose, mixture of microcrystalline cellulose and guar gum; one or more polyhydric alcohols selected from the group consisting of mannitol, xylitol or sorbitol.
5. The composition of claim 1 comprising the lubricants selected from talc, magnesium stearate, stearic acid or glyceryl behenate.
6. The composition of claim 1 comprising glidants selected from colloidal silicon dioxide or talc.
7. The composition of claim 1 comprising the sweeteners selected from group consisting of sugars such as sucrose, lactose or glucose; cyclamate or salts thereof; saccharin or salts thereof; or aspartame.
8. Rapidly dispersing solid oral pharmaceutical composition comprising ondansetron as free base, microcrystalline cellulose, pregelatinized starch, mannitol, crosspovidone, aspartame, mixture of microcrystalline cellulose and guar gum, sodium lauryl sulphate, colloidal silicon dioxide and magnesium stearate.

9. Rapidly dispersing solid oral pharmaceutical composition comprising Ondansetron as free base, crosspovidone, aspartame, mixture of microcrystalline cellulose and guar gum, sodium lauryl sulphate and magnesium stearate.
10. Rapidly dispersing solid oral composition comprising Olanzapine or a pharmaceutically accepted salts, solvates, enantiomers or mixtures thereof including racemic mixture, in an amount of 1 mg to 25 mg, with at least one pharmaceutically accepted excipients selected from the group consisting of an at least one binder in an amount of 2% to 10%, an at least one dispersing agent in an amount of 5% to 15%, an at least one filler in an amount of 50% to 75%, an at least one glidants or lubricant in an amount of 0.5% to 5% and an at least one sweetener in an amount of 1% to 6%.
11. The composition of claim 10 comprising the binders selected from the group consisting of gelatin, pregelatinized starch, starch paste, starch DC, starch 1500, acacia, tragacanth, guar gum, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, glucose, sucrose, sorbitol, polyvinylpyrrolidone or plasdone S-630.
12. The composition of claim 10 comprising the dispersing agent selected from the group consisting of crosscarmellose sodium, sodium carboxymethyl cellulose, crosspovidone, sodium starch glycolate, hydroxypropylcellulose, hydroxypropylmethylcellulose, xanthan gum, alginic acid, alginates or bentonite.
13. The composition of claim 10 comprising the fillers selected from the group consisting of one or more starch derivatives selected from corn starch, potato starch or rice starch one or more polysaccharides selected from the group consisting of dextrans, maltodextrin, microcrystalline cellulose, powdered cellulose, mixture of microcrystalline cellulose and guar gum; one or more polyhydric alcohols selected from the group consisting of mannitol, xylitol or sorbitol.
14. The composition of claim 10 comprising the lubricants selected from talc, magnesium stearate, stearic acid or glyceryl behenate.
15. The composition of claim 10 comprising glidants selected from colloidal silicon dioxide or talc.
16. The composition of claim 10 comprising the sweeteners selected from group consisting of sugars such as sucrose, lactose or glucose; cyclamate or salts thereof; saccharin or salts thereof; or aspartame.
17. Rapidly dispersing solid oral pharmaceutical composition comprising Olanzapine as free base, microcrystalline cellulose, pregelatinized starch, mannitol, crosspovidone, aspartame,

- 5 mixture of microcrystalline cellulose and guar gum, sodium lauryl sulphate, colloidal silicon dioxide and magnesium stearate.
18. Rapidly dispersing solid oral pharmaceutical composition comprising Olanzapine as free base, croscopolidone, aspartame, mixture of microcrystalline cellulose and guar gum, sodium lauryl sulphate and magnesium stearate.

10

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K9/20 A61K31/4178 A61K31/5513

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 57857 A (YUHAN CORP) 5 October 2000 (2000-10-05) example 5; table 1.1	1-7
Y	---	1-18
X	US 6 190 698 B1 (MORRIS TOMMY CLIFFORD ET AL) 20 February 2001 (2001-02-20) column 4, line 63 -column 5, line 11 examples 1,2	10-15
Y	---	1-18
Y	WO 99 47126 A (CHU JAMES SHUNNAN ;YAMANOUCI SHAKLEE PHARMA (US); LIU FANG YU (US) 23 September 1999 (1999-09-23) cited in the application page 2, line 24 -page 4, line 15 page 14, line 1 -page 15, line 14 example 1 ---	1-18
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

5 December 2002

Date of mailing of the international search report

13/12/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Giménez Miralles, J

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 46213 A (SQUIBB BRISTOL MYERS CO) 22 October 1998 (1998-10-22) page 3, line 22 -page 4, line 20 page 6, line 21 -page 7, line 10 examples -----	1-18
Y	US 5 506 248 A (NIKFAR FARANAK ET AL) 9 April 1996 (1996-04-09) column 5, line 5 - line 20 example 1 -----	1-18

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 0057857	A	05-10-2000	AU 3574500	A	16-10-2000
			WO 0057857	A1	05-10-2000
			US 2002071864	A1	13-06-2002
<hr/>					
US 6190698	B1	20-02-2001	US 5919485	A	06-07-1999
			US 2001018071	A1	30-08-2001
			AP 679	A	28-09-1998
			AT 405606	B	25-10-1999
			AT 902296	A	15-02-1999
			AT 206924	T	15-11-2001
			AU 696601	B2	17-09-1998
			AU 5428096	A	16-10-1996
			BG 62594	B1	31-03-2000
			BG 101901	A	30-10-1998
			BR 9607791	A	07-07-1998
			CA 2216372	A1	03-10-1996
			CH 691217	A5	31-05-2001
			CZ 9703001	A3	17-12-1997
			DE 19681287	T0	19-03-1998
			DE 69615887	D1	22-11-2001
			DE 69615887	T2	11-04-2002
			DK 109097	A	12-11-1997
			DK 733367	T3	26-11-2001
			EA 938	B1	26-06-2000
			EE 9700328	A	15-06-1998
			EP 1093815	A1	25-04-2001
			EP 0733367	A1	25-09-1996
			ES 2164837	T3	01-03-2002
			FI 973749	A	22-09-1997
			GB 2313783	A, B	10-12-1997
			HU 9800410	A2	28-07-1998
			IL 117611	A	23-05-2002
			JP 11502848	T	09-03-1999
			LT 97149	A, B	26-01-1998
			LU 90115	A1	10-09-1997
			LV 11983	A	20-03-1998
			LV 11983	B	20-07-1998
			NO 974363	A	17-11-1997
			NZ 306111	A	25-02-1999
			PL 322579	A1	02-02-1998
			PT 733367	T	28-03-2002
			SE 9703206	A	05-09-1997
			SI 9620041	A	30-06-1998
			SI 733367	T1	30-06-2002
			SK 128297	A3	04-03-1998
			TR 9701018	T1	21-01-1998
			TW 426526	B	21-03-2001
			WO 9629995	A1	03-10-1996
			ZA 9602338	A	22-09-1997
<hr/>					
WO 9947126	A	23-09-1999	US 6465009	B1	15-10-2002
			AU 3197399	A	11-10-1999
			CA 2325577	A1	23-09-1999
			CN 1303275	T	11-07-2001
			EP 1063972	A1	03-01-2001
			FI 20002042	A	18-10-2000
			HU 0102862	A2	28-03-2002
			JP 2002506811	T	05-03-2002

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9947126	A		NO 20004643 A	17-11-2000
			PL 344105 A1	24-09-2001
			WO 9947126 A1	23-09-1999
<hr/>				
WO 9846213	A	22-10-1998	AU 729437 B2	01-02-2001
			AU 6569798 A	11-11-1998
			EP 1007006 A1	14-06-2000
			JP 2002514212 T	14-05-2002
			US 6080427 A	27-06-2000
			WO 9846213 A1	22-10-1998
<hr/>				
US 5506248	A	09-04-1996	AU 6878294 A	09-02-1995
			CA 2129099 A1	03-02-1995
			CN 1118254 A	13-03-1996
			CZ 9401810 A3	15-02-1995
			EP 0638310 A1	15-02-1995
			FI 943569 A	03-02-1995
			HU 70951 A2	28-11-1995
			IL 110376 A	16-08-1998
			JP 7145052 A	06-06-1995
			NO 942854 A	03-02-1995
			NZ 264129 A	28-05-1996
			PL 304508 A1	06-02-1995
			ZA 9405672 A	06-03-1995

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.